Our methodology

Kesho produces evidence-based GLP-1 education for Indian patients. This page explains how we research, write, review, and update content, so you can trust what you read and cite.

1. Source hierarchy

We prioritise sources in this order:

1. Peer-reviewed trials (NEJM, Lancet, JAMA) via PubMed
2. Indian guidelines: ICMR, RSSDI consensus statements
3. Regulatory: CDSCO approvals, PIB advisories
4. International bodies: ADA, EASD (for context, adapted to India)

We do not cite social media, influencer content, or pharmacy marketing as primary evidence.

2. Drug-class framing

All content uses molecule and drug-class language (semaglutide, tirzepatide, liraglutide), not brand rankings or purchase recommendations. This aligns with CDSCO March 2026 guidance against surrogate advertising of GLP-1 medicines.

3. Medical review

Cornerstone guides are reviewed by our medical advisory team led by a DM Endocrinology reviewer before publication. Each article displays review date and references. We update content when guidelines or regulatory advisories change.

4. India-specific adaptation

Western BMI thresholds are not applied blindly. We incorporate thin-fat phenotype, lower ICMR/RSSDI BMI cut-offs, vegetarian nutrition patterns, tiered city cost context, and Schedule H prescription rules.

5. Update cadence

• Cornerstone guides: reviewed quarterly or when CDSCO/guideline updates occur
• Cost ranges: updated semi-annually with market data
• FAQ: expanded based on patient questions and People Also Ask data
• All pages show dateModified in structured data

6. What we do not do

• Prescribe or determine eligibility for GLP-1 therapy
• Sell or link to pharmacies
• Rank brands or promote specific products
• Accept pharma sponsorship for GLP-1 content

Read our full editorial policy or contact us with corrections.